Hannelore I. Bax - Publications

Clinical Characteristics and Management of Non-Tuberculous Mycobacterial Skin and Soft Tissue Infections: A Retrospective Cohort Study.

Journal: Open forum infectious diseases

Published: September 25, 2025

Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus.

Journal: The Journal of antimicrobial chemotherapy

Published: April 16, 2025

Cerebral toxoplasmosis in the twenty-first century.

Journal: AIDS (London, England)

Published: March 08, 2025

Omadacycline enhances the in vitro activity of clofazimine against Mycobacterium abscessus.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: October 29, 2024

Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies.

Journal: The Journal of antimicrobial chemotherapy

Published: September 25, 2024

Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials.

Journal: The Lancet. Respiratory medicine

Published: July 01, 2024

Relative Contributions of the Novel Diarylquinoline TBAJ-876 and its Active Metabolite to the Bactericidal Activity in a Murine Model of Tuberculosis.

Journal: The Journal of infectious diseases

Published: March 18, 2024

Mycobacterium abscessus strain variability in preclinical drug development: does it really matter?

Journal: The Journal of antimicrobial chemotherapy

Published: March 14, 2024

A laboratory perspective on Mycobacterium abscessus biofilm culture, characterization and drug activity testing.

Journal: Frontiers in microbiology

Published: February 27, 2024

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: September 22, 2023

Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteraemia (SAFE trial): protocol for a randomised, controlled, open-label, non-inferiority trial comparing 4 and 6 weeks of antibiotic treatment.

Journal: BMJ open

Published: April 21, 2023

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.

Journal: Science advances

Published: March 15, 2023